Navigation Links
Vermillion Reports Fourth Quarter and Full Year 2011 Results
Date:3/27/2012

cologists — the professionals who help define the standard of care for women with ovarian cancer — ordered OVA1 in 2011. The specialist sub-group of gynecologic oncologists supporting OVA1 also grew by 24 in the fourth quarter, bringing the total to more than 275. Given the relatively short period of time this test has been on the market, this represents strong traction and increasing brand awareness within the gynecologist community. This strong progress was matched by increased OVA1 payer coverage in 2011 and the addition of the Department of Defense payer coverage in January 2012.

"The recent approval of a Category 1 CPT code for OVA1 represents a major step towards broader commercial adoption. This approval was supported by peer-reviewed publications and positive coverage decisions, including Medicare. We expect OVA1's unique CPT code to increase OVA1 test volumes, since it will help streamline claims processing and accelerate further coverage and adoption by private payers. While certainly a major achievement for OVA1, it is also a significant endorsement of the unmet clinical need addressed by this important triage test.

"Since improving payer coverage and reimbursement for OVA1 remains our key strategic initiative in 2012, we are continuing to work closely with our partner, Quest Diagnostics, and our territory development managers to both engage with physician offices during the claims process and as well as better educate payers. We believe this two-pronged approach ultimately drives more favorable coverage decisions. We also recently launched a program to encourage local key opinion leaders to work with regional insurance providers and support coverage of OVA1.

"These comprehensive efforts have resulted in OVA1 payer coverage recently being added by Wellmark in South Dakota and Iowa, bringing the total number of independent BlueCross BlueShield plans to 24 or coverage for approximately 38 million lives. Including Medicare a
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
3. Vermillion Reports Results for the Second Quarter 2011
4. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
5. Vermillion Announces Joining Russell Microcap® Index
6. Vermillion Announces Notice of Allowance for Alzheimer Patent
7. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
8. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
9. Stephens Initiates Coverage on Vermillion
10. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
11. Vermillion Announces Issuance of European Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... of Surrey have discovered how the receptors responsible for ... , The new study, published today in The ... in turn regulates the cycle of all cells in ... the local biological clock and its control are weakened ... in bladder physiology and ageing. , While ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... of the interesting and challenging endeavors as the ... highly impervious properties to the foreign substances. Ocular ... possibility of self medication and minimal use of ... molecular weight drugs and provides specific targeting within ...
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies ... company developing first in class collagenase-based products marketed ... CCH) in the U.S. and XIAPEX ® ... results from a randomized, double-blind Phase 2a study ... or edematous fibrosclerotic panniculopathy. The results showed that ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... N.Y., Jan. 31 Mr. Donald Fresne, ... that the company has recently,obtained from Harvard ... cover certain technologies related to cancer therapy ... developed jointly,by scientists in the Laboratory for ...
... VCs face more competition from private ... equity and hedge ... their investments to the greentech and biotech industries in the,coming year, ... a recent survey by the U.S. audit, tax and advisory,firm KPMG ...
... 31 Schering-Plough,Corporation (NYSE: SGP ) today ... has accepted the Peg-IFN (peginterferon alfa-2b),supplemental Biologics License ... status for the adjuvant treatment of patients with,Stage ... agency,in the fall of 2007., The Priority ...
Cached Biology Technology:Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 2Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... by an international standards process, will be available soon ... invited review published in the OnlineFirst version of ... official journal of the American Society for Parenteral and ... the occurrence of misconnection that can be harmful and ... used to join medical devices, components, and accessories to ...
(Date:8/21/2014)... University have developed a novel and versatile modeling strategy ... creating new materials as well as for studying polyelectrolytes, ... us to model much larger and more complex polyelectrolyte ... Nan Li, lead author of a paper on the ... of Materials Science and Engineering. "This is a big ...
Breaking Biology News(10 mins):Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... In 2007, researchers of the Max Planck Institute ... in exploratory behaviour in great tits. Birds with a ... (DRD4 gene) showed stronger novelty seeking and exploration behaviour ... tested and found in a lab-raised group of birds. ...
... , Some animals, it seems, are going on a ... these are reactions to rapidly rising temperatures due to ... Aviv University,s Department of Zoology, who has been measuring ... areas where climate change is most extreme. , Changes ...
... with anorexia nervosa, paradoxically, have strikingly high levels of fat ... Their findings, based on MRI imaging of the knees of ... same age, appear in the February issue of the ... that an emaciated young woman with almost no subcutaneous fat ...
Cached Biology News:Great tits: birds with character 2Animals cope with climate change at the dinner table 2Anorexics found to have excess fat-- in their bone marrow 2
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
This thermal printer, 120 V, provides a permanent record of the preprogrammed method and run data for the PROTEAN IEF cell. Includes cable and power adaptor....
... iCycler thermal cycler with 384-well reaction module ... applications. It is equipped with an interchangeable, ... features algorithm temperature monitoring and control and ... sample volumes. It includes the iCycler base ...
Biology Products: